Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway

Journal of Virology

Volumn 85, Issue 17, 2011, Pages 9114-9126

  Lin, Pi Han ^a   Ke, Yi Yu ^c   Su, Chun Ting ^a   Shiao, Hui Yi ^c   Hsieh, Hsing Pang ^c   Chao, Yu Kai ^a   Lee, Chun Nan ^a,b   Kao, Chuan Liang ^a,b   Chao, Yu Sheng ^c   Chang, Sui Yuan ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BPRHIV 001; COUMARIN DERIVATIVE; MESSENGER RNA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN KINASE B; PROTEIN P300; RNA BINDING PROTEIN; RNA BINDING PROTEIN TAT; RNA POLYMERASE II; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ACETYLATION; ALLOSTERISM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RNA TRANSLATION; TRANSACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; COUMARINS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; ONCOGENE PROTEIN V-AKT; P300-CBP TRANSCRIPTION FACTORS; PHOSPHORYLATION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80052286458     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00175-11     Document Type: Article

References (76)

1. Afeltra, J., R. G. Vitale, J. W. Mouton, and P. E. Verweij. 2004. Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob. Agents Chemother. 48:1335-1343.
2. Alessi, D. R., et al. 1997. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol. 7:776-789.
3. Anderson, K. E., J. Coadwell, L. R. Stephens, and P. T. Hawkins. 1998. Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Curr. Biol. 8:684-691.
4. Angiolini, M., et al. 2010. Structure-based optimization of potent PDK1 inhibitors. Bioorg. Med. Chem. Lett. 20:4095-4099.
5. Baba, M., et al. 1998. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol. Pharmacol. 53:1097-1103.
6. Bayascas, J. R., et al. 2008. Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol. Cell. Biol. 28:3258-3272.
7. Berkhout, B., and S. R. K. T. Jeang. 1989. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59:273-282.
8. Biondi, R. M., et al. 2002. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J. 21:4219-4228.
9. Brès, V., et al. 2002. Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and PCAF. EMBO J. 21:6811-6819.
10. Brooks, B. R., et al. 1983. CHARMM: a program for macromolecular energy minimization and dynamics calculations. J. Comp. Chem. 4:187-271.
11. Casamayor, A., N. A. Morrice, and D. R. Alessi. 1999. Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem. J. 342(2):287-292.
12. Chao, S. H., et al. 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275:28345-28348.
13. Chen, J., S. S. Halappanavar, J. R. St.-Germain, B. K. Tsang, and Q. Li. 2004. Role of Akt/protein kinase B in the activity of transcriptional coactivator p300. Cell. Mol. Life Sci. 61:1675-1683.
14. Chugh, P., et al. 2008. Akt inhibitors as an HIV-1 infected macrophagespecific anti-viral therapy. Retrovirology 5:11.
15. Chugh, P., et al. 2007. Infection of human immunodeficiency virus and intracellular viral Tat protein exert a pro-survival effect in a human microglial cell line. J. Mol. Biol. 366:67-81.
16. Col, E., et al. 2001. The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat. J. Biol. Chem. 276:28179-28184.
17. Contreras, X., et al. 2009. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284:6782-6789.
18. Deng, L., et al. 2000. Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 277:278-295.
19. Egger, M., et al. 2002. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360:119-129.
20. Feinberg, M. B., D. Baltimore, and A. D. Frankel. 1991. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc. Natl. Acad. Sci. U. S. A. 88:4045-4049.
21. Feldman, R. I., et al. 2005. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem. 280:19867-19874.
22. Flexner, C. 2007. HIV drug development: the next 25 years. Nat. Rev. Drug Discov. 6:959-966.
23. François, F., and M. E. Klotman. 2003. Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages. J. Virol. 77:2539-2549.
24. Gao, X., and T. K. Harris. 2006. Role of the PH domain in regulating in vitro autophosphorylation events required for reconstitution of PDK1 catalytic activity. Bioorg. Chem. 34:200-223.
25. Grant, R. M., et al. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
26. Hall, M. J., R. F. Middleton, and D. Westmacott. 1983. The fractional inhibitory concentration (FIC) index as a measure of synergy. J. Antimicrob. Chemother. 11:427-433.
27. Hamy, F., et al. 2000. Blocking HIV replication by targeting Tat protein. Chem. Biol. 7:669-676.
28. Heredia, A., et al. 2005. Indirubin-3′-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 19:2087-2095.
29. Hindie, V., et al. 2009. Structure and allosteric effects of low-molecularweight activators on the protein kinase PDK1. Nat. Chem. Biol. 5:758-764.
30. Hwang, S., et al. 2003. Discovery of a small molecule Tat-trans-activationresponsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J. Biol. Chem. 278:39092-39103.
31. Iyer, N. G., et al. 2007. p300 is required for orderly G1/S transition in human cancer cells. Oncogene 26:21-29.
32. Jayaraman, G. C., et al. 2006. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J. Acquir. Immune Defic. Syndr. 42:86-90.
33. Jeang, K. T., H. Xiao, and E. A. Rich. 1999. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J. Biol. Chem. 274:28837-28840.
34. Ji, M., et al. 2008. Myostatin induces p300 degradation to silence cyclin D1 expression through the PI3K/PTEN/Akt pathway. Cell. Signal. 20:1452-1458.
35. Kiernan, R. E., et al. 1999. HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J. 18:6106-6118.
36. Kitagawa, M., S. H. Lee, and F. McCormick. 2008. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol. Cell 29:217-231.
37. Komander, D., et al. 2004. Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J. 23:3918-3928.
38. Komander, D., et al. 2003. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem. J. 375:255-262.
39. Larkin, J., et al. 2003. Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J. Interferon Cytokine Res. 23:247-257.
40. Little, S. J., et al. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
41. Lucas, A., et al. 2010. Targeting the PI3K/Akt cell survival pathway to induce cell death of HIV-1 infected macrophages with alkylphospholipid compounds. PLoS One 5:e13121.
42. Luo, W., H. Yang, K. Rathbun, C. P. Pau, and C. Y. Ou. 2005. Detection of human immunodeficiency virus type 1 DNA in dried blood spots by a duplex real-time PCR assay. J. Clin. Microbiol. 43:1851-1857.
43. Maira, S. M., et al. 2001. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 294:374-380.
44. Meuillet, E. J., et al. 2010. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol. Cancer Ther. 9:706-717.
45. Mocroft, A., et al. 2003. Decline in the AIDS and death rates in the Euro-SIDA study: an observational study. Lancet 362:22-29.
46. Nagashima, K., et al. 2010. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J. Biol. Chem. doi:10.1074/jbc.M110.156463.
47. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
48. Ott, M., et al. 1999. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr. Biol. 9:1489-1492.
49. Palella, F. J., Jr, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
50. Park, J., et al. 2001. Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 and their role in regulating kinase activity. J. Biol. Chem. 276:37459-37471.
51. Peng, J., Y. Zhu, J. T. Milton, and D. H. Price. 1998. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 12:755-762.
52. Poizat, C., P. L. Puri, Y. Bai, and L. Kedes. 2005. Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells. Mol. Cell. Biol. 25:2673-2687.
53. Prasad, N., R. S. Topping, D. Zhou, and S. J. Decker. 2000. Oxidative stress and vanadate induce tyrosine phosphorylation of phosphoinositide-dependent kinase 1 (PDK1). Biochemistry 39:6929-6935.
54. Rameh, L. E., K. F. Tolias, B. C. Duckworth, and L. C. Cantley. 1997. A new pathway for synthesis of phosphatidylinositol-4,5-bisphosphate. Nature 390:192-196.
55. Richman, D. D., et al. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401.
56. Richter, S., et al. 2004. Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob. Agents Chemother. 48:1895-1899.
57. Richter, S., Y. H. Ping, and T. M. Rana. 2002. TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc. Natl. Acad. Sci. U. S. A. 99:7928-7933.
58. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101.
59. Shet, A., et al. 2006. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J. Acquir. Immune Defic. Syndr. 41:439-446.
60. Shih, S. R., et al. 2010. BPR2-D2 targeting viral ribonucleoprotein complexassociated function inhibits oseltamivir-resistant influenza viruses. J. Antimicrob. Chemother. 65:63-71.
61. Snowden, A. W., and N. D. Perkins. 1998. Cell cycle regulation of the transcriptional coactivators p300 and CREB binding protein. Biochem. Pharmacol. 55:1947-1954.
62. Sodroski, J., et al. 1985. Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science 227:171-173.
63. Stambolic, V., et al. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39.
64. Stephens, L., et al. 1998. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279:710-714.
65. Sühnel, J. 1990. Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res. 13:23-39.
66. Violin, M., et al. 2004. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 18:227-235.
67. Wallace, A. C., R. A. Laskowski, and J. M. Thornton. 1995. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8:127-134.
68. Wang, D., et al. 2001. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75:7266-7279.
69. Wang, W. K., et al. 2000. Interaction between HIV type 1 glycoprotein 120 and CXCR4 coreceptor involves a highly conserved arginine residue in hypervariable region 3. AIDS Res. Hum. Retroviruses 16:1821-1829.
70. Wei, P., M. E. Garber, S. M. Fang, W. H. Fischer, and K. A. Jones. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451-462.
71. Weinstock, H. S., et al. 2004. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J. Infect. Dis. 189:2174-2180.
72. Wensing, A. M., et al. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. 192:958-966.
73. Yang, B., S. Singh, R. Bressani, and G. D. Kanmogne. 2010. Cross-talk between STAT1 and PI3K/AKT signaling in HIV-1-induced blood-brain barrier dysfunction: role of CCR5 and implications for viral neuropathogenesis. J. Neurosci. Res. 88:3090-3101.
74. Yuan, D., et al. 2007. The design, synthesis, and biological evaluation of novel substituted purines as HIV-1 Tat-TAR inhibitors. Bioorg. Med. Chem. 15:265-272.
75. Yuan, Z. M., et al. 1999. Function for p300 and not CBP in the apoptotic response to DNA damage. Oncogene 18:5714-5717.
76. Zhu, Y., et al. 1997. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11:2622-2632.